Meda has launched a new cold sore treatment made by commercialization partner Medivir, Medivir said Tuesday.
Drug maker Valeant Pharmaceuticals International has acquired U.S. and Canadian rights to certain formulations of a GlaxoSmithKline drug used to treat cold sores.
An investigative treatment for hepatitis C got strong results in patients who had failed previous...
Drug makers Valeant Pharmaceuticals International and Kadmon Pharmaceuticals will collaborate to develop antiviral drugs for...
The Food and Drug Administration has approved an additional use for a hepatitis drug....
The Hart-Scott-Rodino waiting period for Bristol-Myers Squibb’s acquisition of Seattle-based biotech company ZymoGenetics has expired,...
The Food and Drug Administration has approved new dosing recommendations for children and adolescents using...
The Food and Drug Administration has approved a generic drug for treating skin diseases made...
Bristol-Myers Squibb will acquire Seattle-based biotech ZymoGenetics, Bristol said Wednesday....
A generic drug maker has filed an abbreviated new drug application for its version of...
An investigational drug made by Pharmasset for treating hepatitis C will get expedited review from...
The Food and Drug Administration is allowing kidney transplant patients to use a drug for...
An investigational drug in late-stage clinical trials increased the cure rate in patients with hepatitis...
The Food and Drug Administration has approved a generic version of a drug for herpes...
A majority of people taking an investigational treatment for hepatitis C were cured after taking...
Sandoz announced Tuesday that it launched a generic drug for treating genital herpes....
Teva Pharmaceuticals has introduced a generic version of a drug for genital herpes, shingles and...
The market for hepatitis C drugs could get a boost if a clinical trial program...
The Food and Drug Administration has given E. Fougera & Co. approval for the first...
Meda plans to work with Medivir to commercialize a cold-sore drug in North America, the...